![Clinical Trial Alert: Phase 2 Study of Vamorolone in Adults with BMD - Quest | Muscular Dystrophy Association Clinical Trial Alert: Phase 2 Study of Vamorolone in Adults with BMD - Quest | Muscular Dystrophy Association](https://mdaquest.org/wp-content/uploads/2022/11/1OkqFGdQ-1024x512.jpeg)
Clinical Trial Alert: Phase 2 Study of Vamorolone in Adults with BMD - Quest | Muscular Dystrophy Association
![Santhera Shares Community Update on Phase 2b Trial for Vamorolone - Parent Project Muscular Dystrophy Santhera Shares Community Update on Phase 2b Trial for Vamorolone - Parent Project Muscular Dystrophy](https://www.parentprojectmd.org/wp-content/uploads/2021/02/blog_santhera-2021.png)
Santhera Shares Community Update on Phase 2b Trial for Vamorolone - Parent Project Muscular Dystrophy
![VISION-DMD – Designed to ensure a timely & cost-effective drug development for Duchenne muscular dystrophy VISION-DMD – Designed to ensure a timely & cost-effective drug development for Duchenne muscular dystrophy](https://vision-dmd.info/vision1/wp-content/uploads/2018/03/brochure-front-e1532944214613.jpg)
VISION-DMD – Designed to ensure a timely & cost-effective drug development for Duchenne muscular dystrophy
![ReveraGen BioPharma's DMD Drug Vamorolone Gets FDA Fast Track Designation - Muscular Dystrophy Association ReveraGen BioPharma's DMD Drug Vamorolone Gets FDA Fast Track Designation - Muscular Dystrophy Association](https://s3.amazonaws.com/mda-strongly/wp-content/uploads/2017/03/27130859/MicroscopeCloseup.jpg)
ReveraGen BioPharma's DMD Drug Vamorolone Gets FDA Fast Track Designation - Muscular Dystrophy Association
![Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug - ScienceDirect Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1043661818309757-ga1.jpg)
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug - ScienceDirect
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study | PLOS Medicine
![Investigational steroid mirrors prednisone's benefits while taming its side effects | Children's National Investigational steroid mirrors prednisone's benefits while taming its side effects | Children's National](https://childrensnational.org/-/media/cnhs-site/images/newsroom/childrens-newsroom-2018/pg_cover_rev25sept18.jpg?h=288&la=en&w=250&hash=7AF4439DF6DCF6EDC6FF1F9ACAF21DCC716B632B)
Investigational steroid mirrors prednisone's benefits while taming its side effects | Children's National
![Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. - Abstract - Europe PMC Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8790668/bin/jamanetwopen-e2144178-g001.jpg)